577691-56-6

Basic information

• Product Name: cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate
• Synonyms: (3S,4R)-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate;cis-tert-butyl 4-fluoro-3-hydroxypiperidine-1-carboxylate;cis-1,1-Dimethylethyl 4-amino-3-fluoro-1-piperidinecarboxylate;cis-tert-butyl 4-aMino-3-fluoropiperidine-1-carboxylate;cis-4-AMino-1-Boc-3-fluor...;cis-4-AMino-1-Boc-3-fluoropiperidine;cis-1-Boc-4-fluoro-3-hydroxypiperidine;Cis-1-Boc-4-aMino-3-fluoropiperidine
• CAS NO: 577691-56-6
• Molecular Formula: C10H19FN2O2
• Molecular Weight: 218.27
• Mol File: 577691-56-6.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 285.587 °C at 760 mmHg
• Flash Point: 126.519 °C
• Appearance: /
• Density: 1.11
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.88±0.40(Predicted)
• CAS DataBase Reference: cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate(577691-56-6)
• EPA Substance Registry System: cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate(577691-56-6)

Safety Data

• Hazardous Substances Data: 577691-56-6(Hazardous Substances Data)

Usage

General Description

Cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate is a chemical compound with the molecular formula C12H22FNO2. It is a derivative of piperidine with an added tert-butyl group and a fluorine atom at the 3rd and 4th positions, respectively. cis-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate is commonly used in pharmaceutical research and drug development due to its potential biological activities. It may have applications in the synthesis of new drugs or as a building block for other chemical compounds. Further research and testing are necessary to fully understand the properties and potential uses of this chemical.

InChI:InChI=1/C10H19FN2O2/c1-10(2,3)15-9(14)13-5-4-8(12)7(11)6-13/h7-8H,4-6,12H2,1-3H3/t7-,8+/m0/s1

Upstream product

• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (±)-cis-4-benzylamino-3-fluoropiperidine-1-carboxylic acid tert-butyl ester 
• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 211108-52-0 (3S,4S)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 373604-28-5 3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 
• 211108-52-0 trans-4-benzylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 
• 955029-44-4 (syn)-3-fluoro-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester 
• 211108-52-0 (3R,4R)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 907572-28-5 tert-butyl-(3R,4S)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 
• 907572-24-1 tert-butyl (3S,4R)-4-(benzylamino)-3-fluoro-piperidine-1-carboxylate 
• 1070896-84-2 (anti)-3-fluoro-4-methanesulfonyloxypiperidine-1-carboxylic acid tert-butyl ester 
• 211108-52-0 cis-4-benzylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3R,4R)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3S,4S)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 1260612-08-5 (3R,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 

Relevant articles and documents

Synthesis of a CGRP Receptor Antagonist via an Asymmetric Synthesis of 3-Fluoro-4-aminopiperidine

A practical and efficient enantioselective synthesis of the calcitonin gene-related peptide receptor antagonist 1 has been developed. The key structural component of the active pharmaceutical ingredient is a syn-1,2-amino-fluoropiperidine 4. Two approaches were developed to synthesize this important pharmacophore. Initially, Ru-catalyzed asymmetric hydrogenation of fluoride-substituted enamide 8 enabled the synthesis of sufficient quantities of compound 1 to support early preclinical studies. Subsequently, a novel, cost-effective route to this intermediate was developed utilizing a dynamic kinetic asymmetric transamination of ketone 9. This synthesis also features a robust Ullmann coupling to install a bis-aryl ether using a soluble Cu(I) catalyst. Finally, an enzymatic desymmetrization of meso-diester 7 was exploited for the construction of the γ-lactam moiety in 1.

PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2

The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these

INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL

Disclosed are compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.